Rankings
▼
Calendar
XERS Q4 2025 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena
XERS
Xeris Biopharma Holdings, Inc.
$960M
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$86M
+42.8% YoY
Gross Profit
$67M
77.8% margin
Operating Income
$17M
19.5% margin
Net Income
$11M
12.9% margin
EPS (Diluted)
$0.06
QoQ Revenue Growth
+15.4%
Cash Flow
Operating Cash Flow
$20M
Free Cash Flow
$20M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$384M
Total Liabilities
$370M
Stockholders' Equity
$14M
Cash & Equivalents
$111M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$86M
$60M
+42.8%
Gross Profit
$67M
$51M
+31.8%
Operating Income
$17M
$2M
+899.0%
Net Income
$11M
-$5M
+316.7%
Revenue Segments
Product
$83M
86%
Keveyis
$13M
13%
Product, Other
$651,000
1%
← FY 2025
All Quarters